A 68Ga-labeled GRPR antagonist (NOTA-PEG3-RM26) was also shown to be a more promising candidate than a 68Ga-labeled agonist (NOTA-Aca-BBN7-14) for imaging of prostate cancer [36]. Here, GRPR is linked to prostate cancer.